Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | HINT1 | P49773 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115345 | 0.93 | TAS1R3 (0.52) | TAS1R3TAS1R1TAAR1TYMPHINT1 | |
| SCHEMBL441421 | 0.91 | TYMP (0.48) | TAS1R3TAS1R1KDM4ETAAR1TYMP | |
| SCHEMBL2113123 | 0.88 | KDM4E (0.50) | TAS1R3TAS1R1KDM4ETAAR1TYMP | |
| SCHEMBL9116771 | 0.88 | KDM4E (0.42) | TAS1R3TAS1R1KDM4ETAAR1TYMP | |
| SCHEMBL9155236 | 0.88 | TAS1R3 (0.36) | TAS1R3TAS1R1KDM4ETAAR1 | |
| SCHEMBL8669174 | 0.86 | TAAR1 (0.51) | TAAR1TYMPHINT1 | |
| SCHEMBL14722197 | 0.86 | TAS1R3 (0.47) | TAS1R3TAS1R1KDM4ETAAR1TYMP | |
| SCHEMBL5963306 | 0.85 | TYMP (0.44) | TAS1R3TAS1R1KDM4ETAAR1TYMP | |
| SCHEMBL9294603 | 0.85 | TYMP (0.44) | TAS1R3TAS1R1KDM4ETAAR1TYMP | |
| SCHEMBL2115347 | 0.83 | TAS1R3 (0.54) | TAS1R3TAS1R1TAAR1TYMPHINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2023-06-22 | — | — | US | disclosed |
| US-11208654-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200032255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2020-01-30 | — | — | US | disclosed |
| US-10253318-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180142239-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2018-05-24 | — | — | US | disclosed |
| US-9688982-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2017-06-27 | — | — | US | disclosed |
| US-9200279-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200280-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140287987-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-09-25 | — | — | US | disclosed |
| US-8748405-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140128324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140066592-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2014-03-06 | — | — | US | disclosed |
| US-20120065125-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110071210-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2125855-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080214436-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008094254-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE (US) | 2008-08-07 | — | — | WO | disclosed |
| US-6379931-B1 | Chimeric DNA/RNA ribozymes containing propanediol | CITY OF HOPE | 2002-04-30 | — | — | US | disclosed |
| EP-0633890-B1 | SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | ZENECA LTD (GB) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214436-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
| US-20120065125-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
| US-20140066592-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
| US-20180142239-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
| US-11208654-B2 | Methods and compositions for the treatment of cancer or other diseases | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
| US-20140287987-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
| US-20200032255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
| US-20110071210-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
| US-20140128324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
| US-10253318-B2 | Methods and compositions for the treatment of cancer or other diseases | HLA-DRB1, CD47, IL2 | TAS1R3 3660/4885TAS1R1 3981/4885KDM4E 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.